Novavax, Inc. (NASDAQ:NVAX) saw unusually large options trading activity on Monday. Traders acquired 1,217 put options on the stock. This represents an increase of 1,366% compared to the average volume of 83 put options.

In other news, CFO John Trizzino sold 5,578 shares of Novavax stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $5.72, for a total transaction of $31,906.16. Following the transaction, the chief financial officer now owns 4,800 shares in the company, valued at approximately $27,456. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP John A. Herrmann III sold 3,643 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $7.07, for a total value of $25,756.01. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,770 shares of company stock worth $132,123. Company insiders own 3.30% of the company’s stock.

A number of hedge funds have recently bought and sold shares of NVAX. State Street Corp increased its position in shares of Novavax by 3.4% during the 3rd quarter. State Street Corp now owns 424,189 shares of the biopharmaceutical company’s stock worth $2,129,000 after purchasing an additional 14,066 shares during the last quarter. Creative Planning boosted its holdings in shares of Novavax by 16.5% in the 3rd quarter. Creative Planning now owns 92,344 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 13,101 shares during the last quarter. Ontario Teachers Pension Plan Board acquired a new stake in shares of Novavax in the 2nd quarter valued at approximately $510,000. A.R.T. Advisors LLC acquired a new stake in shares of Novavax in the 2nd quarter valued at approximately $435,000. Finally, GSA Capital Partners LLP bought a new position in shares of Novavax in the second quarter valued at $197,000. Hedge funds and other institutional investors own 26.74% of the company’s stock.

A number of research analysts have weighed in on NVAX shares. HC Wainwright lifted their price target on shares of Novavax from $10.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Cantor Fitzgerald reissued a “neutral” rating on shares of Novavax in a research report on Thursday, October 17th. Zacks Investment Research lowered shares of Novavax from a “hold” rating to a “sell” rating in a report on Friday, October 25th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $27.50 target price on shares of Novavax in a research note on Friday, November 8th. Finally, B. Riley assumed coverage on Novavax in a report on Wednesday, November 27th. They issued a “buy” rating and a $12.00 price target on the stock. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company. Novavax currently has a consensus rating of “Hold” and an average price target of $28.85.

Novavax stock opened at $5.22 on Tuesday. The company has a market cap of $128.90 million, a price-to-earnings ratio of -0.52 and a beta of 1.96. The firm has a 50-day moving average of $4.34 and a 200-day moving average of $5.21. Novavax has a one year low of $3.54 and a one year high of $51.60.

Novavax (NASDAQ:NVAX) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.24. The company had revenue of $2.51 million for the quarter, compared to the consensus estimate of $4.40 million. During the same quarter in the previous year, the company posted ($2.40) EPS. Analysts expect that Novavax will post -5.7 earnings per share for the current year.

About Novavax

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Recommended Story: Are analyst ratings accurate?

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.